HEAD OF DRUG DEPARTMENT OF GENERAL HEALTH INSURANCE GENERAL DIRECTORATE MR. PHARMACY. WE VISITED AYFER KALABALIK IN HIS OFFICE

General Health Insurance General Directorateü Medicineç Head of Department, Mr. Pharmacist. We visited Ayfer Kalabalık in her office.

The provision of a second treatment option for SMA patients with the Health Practice Communiqué (SUT) update dated 26 April 2025 is considered a positive development; However, it has been stated that the new criteria introduced with the same regulation include restrictive conditions that were not included in the previous practices, and that this may create restrictions in accessing treatment for some patients.

During the visit, treatment criteria in Turkey were compared with foreign practices. evaluated; Our request that the new criteria for access to both Nusinersen and Risdiplam treatments should be reconsidered in the light of patient benefit and scientific data was shared with Mr. Kalabalık.

We attended the visit on behalf of our foundation; Deputy Chairman of the Board of Directors Ece Soyer Demir, Secretary General of the Board of Directors Mehmet Demir, Social Supports Coordinator; Nazlı Demir and Corporate Communications Specialist Çiğdem Çetil;it attended.

Dear Pharmacist for the kind hosting. We would like to thank Ayfer Kalabalık.